Search results for: 'pacif software'

The regulatory technology market in life sciences has, over the last five years, quietly transformed from a back-office category dominated by document repositories and submission publishing tools to one of the most consequential software segments serving the pharmaceutical, biotech, and medical device industries. What started in the late 1990s as a...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping biomanufacturing, cell and gene therapy, precision immunotherapy, anti-infectives, and neurotherapeutics across oncology, infectious disease, nephrology, and neurodegenerative disease. It hi...

15 May 2025  |  Global  |  Market Research

Immunomodulator Therapeutics Market, Global, 2024–2030

Mechanism-targeted Approaches are Driving Transformational Growth by Enabling Innovation in Autoimmune, Oncology, and Inflammatory Therapies

Infographics

×

This research service offers a comprehensive analysis of the global immunomodulator therapeutics market, specifically targeting inflammatory disorders in the immunology, gastrointestinal (GI), and dermatology segments. The report defines this market through products designed to modify and regulate pathological immune responses, either by inhibiting...

08 Sep 2025  |  Global  |  Market Research

Growth Opportunities in Global Protein and Peptide Therapeutics, Forecast to 2030

Cross-Therapeutic Expansion is Driving Transformational Growth Fueled by Novel Formats and Smarter Delivery

Infographics

×

The protein and peptide therapeutics industry is undergoing a profound transformation, driven by next-generation biologics, including multi-specific antibodies, antibody-drug conjugates (ADCs), and GLP-1 treatments. These advances are intensifying competition, while the patent expiries of blockbuster antibodies are accelerating the entry of biosimi...

The bio‑CDMO industry is entering an era of accelerated growth driven by the global shift toward complex biologics, including monoclonal antibodies, antibody-drug conjugates (ADCs), cell and gene therapies, recombinant proteins, and advanced vaccines. Large molecules are projected to record a 10.3% CAGR between 2025 and 2031, signaling sustained de...

In this analysis, Frost & Sullivan identifies and defines the leading trends shaping the global pharmaceutical landscape. The study period is 2022–2030, with 2024 as the base year and 2025–2028 as the forecast period. The geographic scope includes 5 regions: North America, Latin America (LATAM) and the Caribbean, Asia-Pacific (APAC), Europe, and th...

The global small‑molecule CDMO industry is undergoing a structural transformation driven by increasing molecular complexity, patent expiries, cost pressures, and the strategic need to secure resilient pharmaceutical supply chains. Demand is shifting beyond high‑volume commodity generics toward specialized development and manufacturing capabilities ...

Worldwide cancer incidence is expected to exceed 35 million new cases by 2050, a 77% rise from the 20 million cases in 2022. Alcohol intake, tobacco usage, obesity, and air pollution are the main causes of this increase. Cancer studies today emphasize cell and gene therapy, antibody-drug conjugates (ADCs), checkpoint inhibitors, and multi-specific...